Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company headquartered in Los Angeles, California, focused on developing novel therapeutics for cancer patients. The company's mission is to create treatments that reverse the inhibitory effects of cancer on the immune system, addressing critical challenges in oncology such as drug resistance and immune ...Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company headquartered in Los Angeles, California, focused on developing novel therapeutics for cancer patients. The company's mission is to create treatments that reverse the inhibitory effects of cancer on the immune system, addressing critical challenges in oncology such as drug resistance and immune suppression. Initially incorporated in 2013 under the name NanoGB13, Inc., the company was renamed Kairos Pharma in July 2016. The company went public in September 2024, listing on the NYSE American under the symbol KAPA. Kairos Pharma's therapeutic portfolio includes antibodies and small molecules targeting various malignancies, including prostate, lung, and breast cancer, as well as glioblastoma. The company leverages structural biology to design therapies that overcome resistance mechanisms, aiming to restore the body's immune response against tumors. Key leadership includes CEO and Chairman John S. Yu, who is also a neurosurgeon, along with CFO Doug Samuelson, VP of R&D Ramchandran Murali, and Chief Scientific Officer Neil Bhowmick. The company has a small team of approximately 4 employees, reflecting its early-stage nature. As a clinical-stage company, Kairos Pharma has not yet generated revenue, reporting zero revenue and negative net income, with a market cap of around $7.6 million. The company's financials show negative free cash flow and an enterprise value of approximately $5 million, indicating ongoing investment in research and development. Despite its small size, Kairos Pharma aims to make a significant impact in the oncology space by focusing on innovative approaches to overcome drug resistance and enhance immune response, ultimately improving outcomes for cancer patients.
